Results 21 to 30 of about 21,933 (136)

Green biosynthesis of magnetic iron oxide nanoparticles using Mentha longifolia for imatinib mesylate delivery

IET Nanobiotechnology, 2022
In this work, the rapid, facile, and eco‐friendly green process was introduced in the preparation of β‐cyclodextrin/magnetic iron oxide nanoparticles by using the aqueous Mentha longifolia extracts of Mentha longifolia.
Bahareh Naeimipour, Elham Moniri, Ali Vaziri Yazdi, Raheleh Safaeijavan, Hossein Faraji   +4 more
doaj   +1 more source

Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

PLoS ONE, 2014
Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin, Gatien Moriceau, Benjamin Ory, Céline Charrier, Régis Brion, Frederic Blanchard, Françoise Redini, Dominique Heymann   +7 more
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +2 more sources

Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report

Journal of Medical Case Reports, 2011
Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Maazaz Khalid, Znati Kaoutar, Ossaden Abdelmalek, Touyar Anas, El Mrabet Fatima, Akasbi Yousra, Brahmi Sami, El Mesbahi Omar, Amarti Affaf, Tizniti Siham, Taleb Khalid, Ibrahimi Adil   +11 more
doaj   +1 more source

Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018
Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park, Jin Il Kim, Dae Yong Cheung, Soo-Heon Park   +3 more
doaj   +1 more source

SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST

Hematology, Transfusion and Cell Therapy, 2022
Case report Gastrointestinal stromal tumors (GISTs) occur exceedingly rare in children and adolescents. Eighty five percent of pediatric GISTs and 15 % of adult GISTs lack oncogenic mutations in KIT and PDGFRA.
Melek Yaman Ortakoylu, Sonay Incesoy Ozdemir, Handan Dincaslan, Nurdan Tacyildiz, Isınsu Kuzu, Emel Cabi Unal   +5 more
doaj   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Dempke, Wolfram, Linke, Rolf
core   +1 more source

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]

, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core   +1 more source

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34⁺ cells.
Holyoake, T.L., Davies, A., Jordanides, N.E., Giannoudis, A., Jorgensen, H.G., Harris, R.J., Hatziieremia, S., Mountford, J.C., Pirmohamed, M., Clark, R.E., Lucas, C.M.   +10 more
core   +2 more sources

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

BMC Cancer, 2010
Background About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST.
Jiang Ming, Zhou Lin, Yang Yu, Zhu Jiang, Hou Mei   +4 more
doaj   +1 more source